Novel approaches to the use of AI in oncology may require discussion and ultimately modification of existing proprietary and regulatory barriers.
Commentary|Articles|September 10, 2025
From Growing Survivorship Programs to Practicing Self-Care: A Day in the Life With Oncologist Alicia Morgans, MD, MPH
Author(s)Ashling Wahner
Fact checked by: Courtney Flaherty
Alicia Morgans, MD, MPH, shares her typical work week, the importance of saying yes to career opportunities, and the value of trusted team communication.
Advertisement
Advertisement
Successful and sustainable oncology careers are built upon everyday practices, according to Alicia Morgans, MD, MPH. These practices include balancing focus with flexibility, a concept she applies by compartmentalizing tasks to dedicate focused time to prioritizing patient care, diving into projects of personal interest, and discerning next steps for growth.
Related to this article
Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.
A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.
Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.
The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.
An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.
Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Clinicians and researchers are set to gather for the UCSF-cosponsored International Invasive Lobular Carcinoma Symposium.
Advertisement
Advertisement